SII has signed an agreement to manufacture the potential vaccine developed by Jenner Institute of Oxford University in collaboration with British-Swedish pharma company AstraZeneca.
The researchers, working in an 'unprecedented' vaccine development effort to prevent COVID-19, said they have started screening healthy volunteers (aged 18-55) from Friday for their upcoming trial in the Thames Valley Region of England.
Blood samples taken from a group of UK volunteers given a dose of the vaccine showed that it stimulated the body to produce both antibodies and 'killer T-cells', a senior source from the trial was quoted by The Daily Telegraph as saying.
'This will not be the last time a virus threatens our lives and our livelihoods'
Two male volunteers were administered the vaccine at Bharti Vidyapeeth's Medical College and Hospital, a senior office-bearer of the hospital said.
"I think we'll have a vaccine by the end of the year," Trump said at a Fox News virtual town hall. "We'll have a vaccine much sooner rather than later."
Two men, aged 32 and 48, were given the first shot of the 'Covishield' vaccine, being manufactured by Pune-based Serum Institute of India, at Bharti Vidyapeeth's Medical College and Hospital on Wednesday. The dose will be repeated after one month, an official said.
The phase 3 trial is being implemented as part of Operation Warp Speed, a multi-agency collaboration led by the US Health and Human Services, which aims at accelerating the development and manufacturing of medical countermeasures for COVID-19 and delivering 300 million doses of an effective vaccine by January 2021.
'Our client is suffering due to the ill-effects of the vaccine. He has to be compensated for his suffering. Further, a detailed investigation has to be done on the Covishield vaccine and its side-effects,' says the volunteer's advocate.
AstraZeneca and the University of Oxford, as the trial sponsor, said that they cannot disclose further medical information but confirmed that independent investigations concluded that the trials were safe to restart.
Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa.
The United Kingdom government has pledged 20 million to support the "ChAdOx1 nCoV-19" coronavirus vaccine trial programme, with UK Health Secretary Matt Hancock saying the government would "throw everything at" finding a vaccine against the deadly virus.
The researchers found that after being exposed to high levels of the novel coronavirus, none of the six monkeys that were given the vaccine developed viral pneumonia. Also, there was no sign that the vaccine had made the animals more vulnerable.
A team at Bristol University used recently developed techniques to validate that the vaccine accurately follows the genetic instructions programmed into it by the Oxford University team.
Alleging that the candidate vaccine was not safe, he has also sought cancelling approval for its testing, 'manufacture and distribution', failing which legal action would be taken.
Early data from its vaccine candidate 'mRNA-1273' showed it produced protective antibodies in a group of eight healthy volunteers, Moderna said. The other closely watched COVID-19 vaccine is the one being developed by scientists at Oxford University.
'People are already sending congratulatory messages. But I have said, "Please don't until the trials are over".'
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances